This study will test the efficacy, safety, and tolerability of the experimental drug AZD3480 in people with mild to moderate Alzheimer's disease. It will also compare the drug to donepezil as a potential disease-modifying treatment.
|Min Age||Max Age||Gender||Healthy Volunteers|
Accepts Healthy Volunteers
AZD3480 is a novel small molecule that acts selectively on the alpha4beta2 neuronal nicotinic receptor. The effects on cognition will be compared to those of donepezil, which is widely used in the long-term treatment of Alzheimer's disease, during 1 year. The dose of AZD3480 evaluated in this study, a 30-mg capsule, reflects an appropriate dose based on earlier findings. Participants with mild to moderate Alzheimer's have been specifically selected to enhance the likelihood of seeing a difference in effectiveness of AZD3480 compared to donepezil.
|Map Marker||City||State||Zip Code||Primary Contact|
Geolocation is 33.4636012, -112.0535987
Geolocation is 28.5552719, -82.3878709
Geolocation is 25.9812024, -80.148379
Pierre Tariot, MD
Banner Alzheimer's Institute
Gaston Farr, MA